Share the post "Windlas Biotech announced Financial Results Q1 2024"
Highlights
- The presented financial data is Standalone to provide a comprehensive overview of the company performance.
- Sales over the Year and quarter: The company experienced a substantial growth of 20.97 % in the past year, substantial increase in net sales/revenue by 2.26 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 57.51 %. Marginal decrease of -6.91% in other income during this quarter.
- Profit over the Year and quarter: Significant improvement in profitability for Windlas Biotech Limited. Notable increase of 11.71 % in net profit Year to Year, Windlas Biotech Limited’s profitability dropped by -20.47 % Quarter to Quarter.
- EPS over the Year and quarter: EPS increased by 11.74 % Year to Year. EPS decreased by -20.61 % in previous quarter. Analysis needed for shareholder value.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 144.786 Cr | Rs. 171.285 Cr | Rs. 175.153 Cr | + 2.26 % | + 20.97 % |
Expenses | Rs. 127.64 Cr | Rs. 149.35 Cr | Rs. 154.28 Cr | + 3.3 % | + 20.87 % |
Operating Profit | Rs. 17.15 Cr | Rs. 21.94 Cr | Rs. 20.87 Cr | -4.88 % | + 21.69 % |
OPM % | 11.85 % | 12.81 % | 11.92 % | -0.89 % | + 0.07 % |
Other Income | Rs. 2.624 Cr | Rs. 4.44 Cr | Rs. 4.133 Cr | -6.91 % | + 57.51 % |
Interest | Rs. 0.24 Cr | Rs. 0.28 Cr | Rs. 0.49 Cr | + 75 % | + 104.17 % |
Depreciation | Rs. 3.19 Cr | Rs. 3.54 Cr | Rs. 6.21 Cr | + 75.42 % | + 94.67 % |
Profit before tax | Rs. 16.34 Cr | Rs. 22.56 Cr | Rs. 18.3 Cr | -18.88 % | + 12 % |
Tax % | 26.16 % | 24.88 % | 26.39 % | + 1.51 % | + 0.23 % |
Net Profit | Rs. 12.07 Cr | Rs. 16.95 Cr | Rs. 13.48 Cr | -20.47 % | + 11.68 % |
EPS in Rs | Rs. 5.79 | Rs. 8.12 | Rs. 6.44 | -20.69 % | + 11.23 % |
Today, we’re looking at Windlas Biotech Limited’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 20.97 %. However, it did see a marginal increase of 2.26 % from the previous quarter. Expenses ticked up slightly by 3.3 % quarter-on-quarter, aligning with the annual rise of 20.87 %. Operating profit, while up 21.69 % compared to last year, faced a quarter-on-quarter dip of -4.88 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 0.07 %, but a shrinkage of -0.89 % sequentially. Other income fell by -6.91 % compared to the last quarter, despite an annual growth of 57.51 %. Interest expenses surged remarkably by 75 % from the previous quarter, yet the year-over-year increase remains at a moderate 104.17 %. Depreciation costs climbed by 75.42 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 94.67 %. Profit before tax grew annually by 12 % but saw a reduction from the preceding quarter by -18.88 %.
Tax expenses as a percentage of profits increased slightly by 0.23 % compared to last year, with a more notable quarter-on-quarter increase of 1.51 %. Net profit rose by 11.68 % year-on-year but witnessed a -20.47 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 11.23 % but a quarterly fall of -20.69 %. In summary, Windlas Biotech Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 144.786 Cr | Rs. 171.285 Cr | Rs. 175.153 Cr | + 2.26 % | + 20.97 % |
Expenses | Rs. 127.64 Cr | Rs. 149.35 Cr | Rs. 154.28 Cr | + 3.3 % | + 20.87 % |
Operating Profit | Rs. 17.15 Cr | Rs. 21.94 Cr | Rs. 20.87 Cr | -4.88 % | + 21.69 % |
Net Profit | Rs. 12.07 Cr | Rs. 16.95 Cr | Rs. 13.48 Cr | -20.47 % | + 11.68 % |
EPS in Rs | Rs. 5.79 | Rs. 8.12 | Rs. 6.44 | -20.69 % | + 11.23 % |
In reviewing Windlas Biotech Limited’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 20.97 % year-on-year growth, however, there was a minor increase of 2.26 % from the previous quarter. Expenses rose by 20.87 % compared to the previous year, with a 3.3 % increase quarter-on-quarter. Operating Profit surged by 21.69 % annually, and saw a -4.88 % decrease from the last quarter.
Net Profit showed yearly increase of 11.68 %, and experienced a -20.47 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 11.23 % annually, however dipped by -20.69 % compared to the last quarter. In essence, while Windlas Biotech Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.